Advertisement

Topics

Noonan/Russo Limited Company Profile

12:51 EST 21st November 2017 | BioPortfolio

We help our clients build and implement strategies for managing the flow of information to the financial, media and scientific communities: shareholders, opinion leaders, analysts, investors, venture capitalists, industry collaborators, journalists, healthcare providers, payors and consumers.

Since 1988, Noonan Russo Presence has represented hundreds of companies that have shaped the biotechnology and healthcare sectors and many of the leaders in science and pharmaceuticals. We understand the challenges and complexities of these businesses and the most effective and efficient ways to meet the needs and interests of their key audiences.

Location

15 Basinghall Street
London
EC2V 5BR
United Kingdom

Contact

Phone: 0207 726 4452
Fax: 0207 726 4453


News Articles [24 Associated News Articles listed on BioPortfolio]

Law Professors File Amicus Brief Supporting En Banc Rehearing of Ariosa v. Sequenom

A group of 23 law professors, myself included, have filed an amicus brief in support of en banc rehearing of Ariosa v. Sequenom. The brief is available here.Adam Mossoff, a professor at George Ma...

Amelia Earhart mystery: Forensic dogs scent human remains on remote Pacific island

Four dogs trained to detect the scent of human bones have located a site on a remote Pacific atoll where Amelia Earhart and her navigator, Fred Noonan, may have died on their ill-fated attempt to circ...

AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

At the Company:AmpliPhi BiosciencesMatthew Dansey, 858-800-4869md@ampliphibio.comorInvestor Relations:LHA Investor RelationsJody Cain, 310-691-7100jcain@lhai.comorMedia:Russo Part...

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the developmen...

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...

Quotient Limited to Participate in the Jefferies 2017 London Healthcare Conference

JERSEY, Channel Islands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Execut...

Quotient Limited Reports Second Quarter Fiscal 2018 Financial Results

MosaiQ project de-risked, Verification and Validation (“V&V”) “head-to-head” studies confirm targeted concordance levels for all blood grouping assaysEuropean field trials planned to co...

PubMed Articles [15 Associated PubMed Articles listed on BioPortfolio]

Novel mutations and their genotype-phenotype correlations in patients with Noonan syndrome, using next-generation sequencing.

Noonan Syndrome (NS) is an autosomal dominant disorder with many variable and heterogeneous conditions. The genetic basis for 20-30% of cases is still unknown. This study evaluates Iranian Noonan pati...

Noonan syndrome: an update on growth and development.

To provide an update on recent developments on Noonan syndrome with a special focus on endocrinology, bone, and metabolism aspects. The key issues still to be resolved and the future therapeutic persp...

Multiple spinal nerve enlargement and SOS1 mutation: further evidence of overlap between Neurofibromatosis type 1 and Noonan phenotype.

Neurofibromatosis type 1 (NF1) has long been considered a well-defined, recognizable monogenic disorder, with neurofibromas constituting a pathognomonic sign. This dogma has been challenged by recent ...

Noonan Syndrome: An Underestimated Cause of Severe to Profound Sensorineural Hearing Impairment. Which Clues to Suspect the Diagnosis?

To highlight Noonan syndrome as a clinically recognizable cause of severe to profound sensorineural hearing impairment.

Occurrence of Cranial Neoplasms in Pediatric Patients with Noonan Syndrome Receiving Growth Hormone: Is Screening with Brain MRI prior to Initiation of Growth Hormone Indicated?

Noonan syndrome (NS) is associated with short stature. Growth hormone treatment has been FDA approved for use in these patients. Children with NS are at a higher risk of developing benign and malignan...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) – insulin-like growth factor-I (IGF-I) axis resultin...

Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome

This study evaluate the efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors, also known as "statins" in the treatment of growth and skeletal abnormalities in c...

Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes

Noonan and LEOPARD syndromes share, with variable severity, different clinical traits, notably craniofacial manifestations, cardiopathies, short stature, and juvenile cancers. The main ge...

Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

This trial is conducted in Asia. The aim of this trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.

Companies [83 Associated Companies listed on BioPortfolio]

Noonan/Russo Limited

We help our clients build and implement strategies for managing the flow of information to the financial, media and scientific communities: shareholders, opinion leaders, analysts, investors, venture ...

Russo Partners, LLC

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

More Information about "Noonan/Russo Limited" on BioPortfolio

We have published hundreds of Noonan/Russo Limited news stories on BioPortfolio along with dozens of Noonan/Russo Limited Clinical Trials and PubMed Articles about Noonan/Russo Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Noonan/Russo Limited Companies in our database. You can also find out about relevant Noonan/Russo Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


Corporate Database Quicklinks



Searches Linking to this Company Record